$MOLN Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.37 up 9.76% YoY
• Molecular Partners forecasts full-year 2026 total operating expenses of CHF50M at constant exchange rates, including approximately CHF5M of non-cash effective costs; cash is expected to fund operations into late 2027.